Inogen Inc (INGN) executive sells 10,938 shares in planned trade
Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief HR Officer at Inogen Inc (INGN), sold 10,938 shares of company common stock for $6.5959 per share on July 1, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following the sale, Yi Boyer directly holds 5,039 shares of Inogen common stock.
INGN - Inogen Inc Volatility & Greeks
This article provides a detailed overview of Inogen Inc (INGN) financial data, including its stock performance, volatility metrics, and various financial ratios. It covers key figures such as market capitalization, sales, earnings per share, insider and institutional ownership, and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
Inogen Appoints New Chief Operating Officer for Growth
Inogen has appointed Andy Reding as its new Chief Operating Officer, a move aimed at strengthening its leadership and execution capabilities to support diversification, new product launches, and geographic expansion. Reding brings over 30 years of experience in medical technology and respiratory care. His compensation package includes a substantial base salary, performance-based bonus, and restricted stock units, with severance protections designed to attract and retain senior talent.
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen, Inc. (Nasdaq: INGN) has appointed Andy Reding as its new Chief Operating Officer, a newly created role aimed at strengthening leadership and driving commercial and operational execution. Reding brings over 30 years of medical technology and commercial operations experience, previously serving as Chief Commercial Officer at Viant Medical and Vice President and GM at Hillrom Respiratory Health. His appointment is expected to help Inogen diversify its business, enhance execution, and accelerate strategic priorities, including driving top-line growth and expanding the innovation pipeline.
Inogen Appoints Reding to New COO Role
Inogen has appointed Jason Reding as its new Chief Operating Officer, a newly created role within the company. Reding brings extensive experience in general management, operations, and supply chain across various industries, including medical devices. This strategic hire is expected to strengthen Inogen's operational execution and global supply chain management.
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen, Inc. has announced the appointment of Andy Reding as Chief Operating Officer, a newly created role effective July 6, 2026. Reding will be responsible for driving revenue, operational performance, and aligning strategic priorities to enhance execution and accelerate the company's growth. With over 30 years of leadership experience in medical technology, including significant respiratory care expertise, Reding is expected to be instrumental in Inogen's diversification and expansion efforts.
Inogen appoints Andy Reding as chief operating officer
Inogen Inc. has appointed Andy Reding as its new Chief Operating Officer, a newly created position aimed at strengthening its leadership structure. Reding brings over 30 years of experience in medical technology and will be responsible for revenue and operational performance, aligning cross-functional priorities, and translating company strategy into operational outcomes. The company also announced that Reding will receive an inducement equity award of restricted stock units covering 130,000 shares of Inogen’s common stock.
Inogen Inc SEC Filing
This SEC Form 144 filing indicates a proposed sale of 10,770 shares of Inogen Inc. (INGN) common stock by Jennifer Yi Boyer, dated May 29, 2026, under a 10b5-1 plan. The filing also notes 10,938 Restricted Stock Units acquired on March 1, 2025, with Morgan Stanley Smith Barney LLC identified as the broker. The aggregate market value of the shares to be sold is reported as $70,550.10.
Inogen (Nasdaq: INGN) adds COO Andy Reding with equity package
Inogen (Nasdaq: INGN) has appointed Andy Reding as its new Chief Operating Officer, effective July 6, 2026, a newly created role to drive revenue, operations, and cross-functional execution for new products and geographic expansion. Reding's compensation package includes a $500,000 annual base salary, a 70% target bonus, a $100,000 sign-on bonus, and an equity award of 130,000 time-based Restricted Stock Units (RSUs) vesting over three years. The appointment aims to strengthen Inogen's leadership as it diversifies its business and advances its respiratory care strategy.
Inogen, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of Inogen, Inc.'s financial disclosures and filings, including earnings reports, annual general meetings, corporate presentations, and investor conference transcripts from 2022 to 2026. These documents offer insights into the company's financial performance, strategic initiatives, and growth drivers, crucial for informed investment decisions.
Inogen, Inc. Actuals & Estimates (NASDAQ:INGN)
This article provides an overview of Inogen, Inc.'s (NASDAQ: INGN) financial actuals and estimates, including its current stock price, historical performance, analyst forecasts, and upcoming earnings report. It highlights the company's financial data, such as market capitalization, EBITDA, and net income, alongside frequently asked questions about its stock. The content also includes details on volatility, employee count, and guidance on how to trade INGN shares.
Inogen, Inc. Actuals & Estimates (SWB:6IO)
This article provides financial actuals and estimates for Inogen, Inc. (SWB:6IO), including income statement, balance sheet, and cash flow data, alongside analyst price targets. It details the company's past earnings and revenue, future earnings report dates, and key financial metrics like EBITDA. The article also addresses frequently asked questions regarding the stock, such as its ticker, forecast, historical prices, and dividend policy.
Price to sales forward of Inogen, Inc – NASDAQ:INGN
This article displays the "Price to sales forward" metric for Inogen, Inc (NASDAQ: INGN) on the TradingView platform. The content is primarily a representation of financial data for the company, showing a period, value, change, and percentage change without specific figures in the provided text. It is a snapshot from a financial data and charting service.
Enterprise value to revenue forward of Inogen, Inc – NASDAQ:INGN
This article provides financial information for Inogen, Inc (NASDAQ: INGN), specifically its enterprise value to revenue forward. It appears to be a stub or an incomplete data entry from a financial platform like TradingView, as it lacks detailed analytical content beyond the stated metric.
Precision Trading with Inogen Inc (INGN) Risk Zones
This article provides a precision trading analysis for Inogen Inc (INGN), detailing neutral readings in shorter horizons and suggesting an easing of a long-term weak bias. It highlights an exceptional 49.5:1 risk-reward setup targeting a 15.8% gain versus 0.3% risk, and outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also includes a multi-timeframe signal analysis with support and resistance levels.
Inogen Inc (INGN) Institutional Confidence
The article analyzes Inogen Inc's (INGN) institutional confidence score, which is currently 7.00, placing it 79th in its industry. Institutional shareholding rose by 4.39% quarter-over-quarter to 75.89%, with Steven Cohen being the largest shareholder despite a slight decrease in his holdings. The article details the shareholdings and changes for several major institutional investors in INGN.
Inogen Inc (INGN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Inogen Inc (INGN), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, including investment advisors, hedge funds, and corporations, and tracks changes in institutional shareholding over several quarters. Key individual and institutional investors are listed with their shareholdings and recent activity.
Inogen Inc (INGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Inogen Inc's (INGN) revenue breakdown by region, indicating that 60.18% of its revenue comes from the U.S. and 39.82% from non-U.S. sources. It also lists various financial reporting periods (FY2025-FY2020) but states that relevant data for business segments has not yet been disclosed by the company. The current stock price and market capitalization are also presented.
Inogen Inc (INGN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Inogen Inc (INGN), highlighting its current market data and valuation score. The company's valuation score is 8.86, placing it 63rd in the Healthcare Equipment & Supplies industry. Key financial ratios like P/E, P/B, P/S, and P/CF are mentioned, although relevant data for the latter three have not yet been disclosed by the company.
Inogen Inc (INGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Inogen Inc (INGN), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on three analysts, the stock has an average target price of $13.00, with a "Buy" recommendation. The article also includes peer comparisons and answers FAQs regarding expected revenue, price targets, and recent EPS performance.
Inogen Inc Stock (US45780L1044): Valuation metrics under the microscope
This article examines the valuation metrics of Inogen Inc (INGN), a medical technology company specializing in portable oxygen concentrators. Due to recent operating losses, traditional price-earnings ratios are not relevant; instead, investors focus on price-to-sales and enterprise-value-based measures, considering the company's significant net-cash position. The analysis highlights how gross margins, restructuring efforts, and free cash flow volatility impact Inogen's valuation compared to its peers, with the market balancing risks of continued losses against potential operational recovery.
INGN SEC Filings - Inogen Inc 10-K, 10-Q, 8-K Forms
This page on StockTitan provides a comprehensive resource for Inogen Inc. (INGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event disclosures. It details Inogen's business in respiratory medical technology and lists recent filings with AI-generated summaries and sentiment analysis. The page also offers key stock data, such as market capitalization and industry sector, along with rankings and an FAQ section.
Former ZimVie CEO Joins Inogen’s Board of Directors
Inogen Inc. has appointed Vafa Jamali, former CEO of ZimVie and a veteran medical device executive, to its Board of Directors as an independent director. Jamali's appointment aims to leverage his expertise in driving strategic execution and growth, particularly as Inogen transforms into a diversified respiratory care platform. This move is supported by a cooperation agreement with Kent Lake Partners LP, who expressed confidence in Inogen's strategic direction and Jamali's anticipated contributions to its growth and profitability goals.
Inogen (NASDAQ: INGN) holders back equity plan but keep staggered board
Inogen Inc. stockholders approved an expanded 2023 Equity Incentive Plan, adding 750,000 shares for awards, and re-elected two Class III directors. While executive compensation and auditor ratification also passed, a proposal to declassify the board did not receive approval, maintaining the company's staggered board structure. Approximately 76.28% of eligible shares were represented at the annual meeting.
Inogen (INGN) director awarded 28,081 RSUs, boosting share holdings
Inogen director Mira Kirti Sahney was granted 28,081 restricted stock units (RSUs) of Common Stock on June 5, 2026, increasing her direct holdings to 67,805 shares. This transaction, classified as compensation rather than an open-market purchase, vests on the earlier of the one-year anniversary or the day prior to the next Annual Meeting, contingent on her continued service. The grant reinforces her alignment with shareholder interests.
Inogen (NASDAQ: INGN) director awarded 28,081 restricted stock units
Inogen Inc. director Elizabeth Mora was granted 28,081 restricted stock units (RSUs) at no cost, increasing her direct holdings to 107,261 shares. These RSUs will vest in approximately one year, contingent on her continued service. This transaction is considered a neutral event, aligning the director's incentives with shareholder interests without immediate dilution.
Inogen (INGN) director Jamali Vafa receives 28,081-share RSU grant
Inogen director Jamali Vafa was granted 28,081 shares of common stock as a restricted stock unit (RSU) award on June 5, 2026, at no cash cost. Following this award, Vafa directly holds 43,081 shares. The RSUs are set to vest on the earlier of one year after the grant date or the day before the next annual stockholder meeting, contingent upon his continued service.
Inogen (NASDAQ: INGN) director granted 28,081 restricted stock units in equity award
Inogen Inc. director Heather D. Rider was granted 28,081 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 116,282 shares. These RSUs will vest on the earlier of one year from the grant date or the day before the next Annual Meeting of stockholders, contingent upon her continued service. This transaction aligns her incentives with shareholder interests by linking her compensation to the company's equity performance.
Inogen Inc (INGN) awards director Glenn Boehnlein 28,081 stock units
Inogen Inc. director Glenn S. Boehnlein was granted 28,081 shares of Common Stock as a restricted stock unit award on June 5, 2026. The award, valued at $0.00 per share, will vest on the earlier of one year from the grant date or the day before the next Annual Meeting of stockholders, contingent on his continued service. Following this transaction, Boehnlein directly holds 104,966 shares of Inogen common stock.
INGN Analyst Forecast (INGN) — MLQ
The article provides an analyst forecast for INGN, indicating no current consensus ratings (buy, hold, or sell) and no 12-month average price target. It outlines various financial metrics and types of analyst estimates that would typically be included, such as revenue, EBITDA, EPS, and net income, but shows them as unpopulated for INGN. The piece appears to be a template or a snapshot of an undeveloped analyst report for the company.
Inogen Inc stock (US45780L1044): Nasdaq-listed oxygen therapy specialist sees active trading ahead o
Inogen Inc's Nasdaq-listed stock (INGN) has been actively trading in early June 2026, with investors reviewing its financial performance and preparing for the annual shareholder meeting. The company reported $85.1 million in revenue, a 3.4% increase driven by international growth, but continues to post net losses. Key outcomes from the AGM include the approval of directors, auditors, and executive compensation, while a proposal to declassify the board did not pass.
Inogen Welcomes Three New Executive Team Members
Inogen Inc. has appointed three new senior leaders to drive its next phase of growth: Jason Richardson as CFO, Dominic Hulton as Chief Marketing Officer, and Corey Moritz as VP of U.S. Business to Business sales. Richardson, formerly of Baxter International, succeeds Michael Bourque, while Hulton brings over 20 years of commercial leadership from Insulet Corporation. Moritz, a healthcare executive, has a strong track record in commercial transformation and sales team building.
Inogen Inc EVP Jennifer Yi Boyer sells $70,313 of common stock
Jennifer M. Yi Boyer, EVP of Inogen Inc, sold 10,770 shares of company stock for $70,313 on May 29, 2026, under a Rule 10b5-1 trading plan. The stock price has since declined, though InvestingPro analysis suggests the company is undervalued despite recent net losses. This transaction follows mixed Q1 2026 financial results where Inogen surpassed revenue expectations but missed EPS targets.
Inogen Inc EVP Jennifer Yi Boyer sells $70,313 of common stock
Inogen Inc's EVP, Jennifer M. Yi Boyer, sold 10,770 shares of common stock for $70,313 on May 29, 2026, under a Rule 10b5-1 trading plan. The stock has since declined by 7.5%, though InvestingPro analysis suggests it may be undervalued. This comes after Inogen reported mixed Q1 2026 results, beating revenue expectations but missing EPS forecasts.
Inogen Inc EVP Jennifer Yi Boyer sells $70,313 of common stock
Jennifer M. Yi Boyer, EVP and Chief HR Officer at Inogen Inc, sold 10,770 shares of company stock for a total of $70,313 on May 29, 2026, under a Rule 10b5-1 trading plan. Following the sale, she directly holds 15,977 shares. This comes as Inogen reported mixed Q1 2026 results with revenue surpassing expectations but EPS missing projections.
Inogen (INGN) HR chief sells 10,770 shares under Rule 10b5-1 plan
Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief Human Resources Officer at Inogen Inc. (INGN), sold 10,770 shares of common stock on May 29, 2026. The sale, executed under a pre-arranged Rule 10b5-1 trading plan, occurred at a weighted average price of $6.5286 per share, totaling approximately $70,313. Following this transaction, Ms. Boyer directly holds 15,977 shares of Inogen common stock.
[144] Inogen Inc SEC Filing
This article details an Inogen Inc. SEC Form 144 filing, which indicates a proposed sale of securities. The document provides information about the filer, the issuer, the securities to be sold (Common Stock, 10,770 units with an aggregate market value of $70,435.80), and the acquisition details (Restricted Stock Units acquired on May 1, 2024). The filing also contains a representation by the signatory regarding the absence of undisclosed material adverse information.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen (INGN) is positioned for growth due to its strong portable oxygen concentrator (POC) market prospects, expanding product portfolio, and international market momentum, despite U.S. revenue pressures. The company is increasing R&D investment and expects continued business improvements, with an attractive valuation based on its P/S ratio. Key risks include macroeconomic factors, supply chain exposure, and reliance on reimbursement for rental economics.
Inogen stock (US45780L1044): respiratory player in focus after Q1 2026 update and restructuring plan
Inogen has reported its Q1 2026 financial results, revealing shrinking revenues but also progress in cost-cutting and cash preservation. The company, which specializes in portable oxygen concentrators, is undergoing restructuring efforts to align its cost base with current revenue levels in a competitive US respiratory care market. Investors are now evaluating the impact of these changes on the company's future profitability and ability to innovate.
Inogen Q1 2026 slides: revenue beats amid profitability pressure
Inogen Inc. (NASDAQ:INGN) reported mixed Q1 2026 results, with revenue of $85.1 million exceeding expectations but GAAP diluted EPS of $(0.30) missing forecasts due to worsening profitability. International sales surged 17.8%, compensating for a 4.8% decline in U.S. sales, while the company's net loss widened and adjusted EBITDA turned negative. Despite strategic investments in R&D and new product launches like the Aurora CPAP mask, profitability challenges persist, as reflected by the stock's 6.2% decline.
Inogen (INGN) TTM Loss Narrows To US$22.7 Million Testing Bearish Profitability Narratives
Inogen (INGN) reported a trailing twelve-month (TTM) net income loss of US$22.7 million for FY 2025, an improvement from a US$35.9 million loss in FY 2024. Despite this narrower loss, the company remains unprofitable and is forecast to continue so for the next three years, with revenue growth projected at 6.4% annually, slower than the broader US market. The stock trades at a low P/S multiple of 0.6x, significantly below peers and its DCF fair value, reflecting investor concerns about its profitability and growth prospects.
Inogen, Inc. (NASDAQ:INGN) Q1 2026 Earnings Call Transcript
Inogen, Inc. reported Q1 2026 revenue of $85.1 million, a 3.4% year-over-year increase, driven by strong international sales, though U.S. sales and rentals saw declines due to shifting market dynamics. The company reaffirmed its 2026 revenue guidance and anticipates adjusted EBITDA growth for the full year, despite increased R&D and marketing investments for new products like the Aurora CPAP mask and Simeox. Inogen aims to expand its addressable market beyond portable oxygen concentrators by annually launching new products in adjacencies like sleep therapy and airway clearance.
Inogen Inc 1Q 2026: Revenue $85.1M, EPS $(0.30) — 10-Q Summary
Inogen Inc (INGN) reported its first-quarter 2026 financial results, with revenue increasing to $85.1M from $82.3M year-over-year. Despite the revenue growth, the company's net loss widened to $8.3M and diluted loss per share increased to $(0.30) from $(0.25) in the prior year. The report also detailed shifts in geographic sales, product expansion, stable gross margins, and operational actions including a share repurchase program.
Inogen Inc stock (US45780L1044): Q1 revenue growth and valuation debate
Inogen Inc reported strong Q1 revenue growth driven by demand for its portable oxygen concentrators, despite the stock trading below analyst price targets. The company's business model focuses on homecare respiratory products, aligning with long-term healthcare trends. However, profitability concerns, cash flow, and sector-specific risks like reimbursement pressures and regulatory changes temper investor enthusiasm.
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen, Inc. (INGN) reported a wider-than-expected adjusted loss per share of 30 cents for Q1 2026, despite revenues increasing 3.4% year over year to $85.1 million, surpassing analyst estimates. The revenue growth was primarily driven by strong international sales, which offset declines in U.S. sales and rentals, and the company also saw an improvement in its adjusted gross margin. Inogen provided Q2 2026 revenue guidance of $94-$97 million and maintained its full-year 2026 revenue outlook of $366-$373 million.
Inogen: Q1 Earnings Snapshot
Inogen Inc. (INGN) reported a first-quarter loss of $8.3 million, translating to 30 cents per share. The Beverly, Massachusetts-based company, which produces oxygen concentrators, announced revenues of $85.1 million for the period. This financial summary was generated by Automated Insights using data from Zacks Investment Research.
Inogen Q1 2026 presentation shows revenue beat, widening losses
Inogen Inc. reported mixed results for Q1 2026, with revenue exceeding expectations at $85.1 million, driven by strong international sales growth of 17.8%. However, the company experienced widening losses, with a diluted EPS of $(0.30) and increased operating expenses due to investments in R&D and strategic initiatives like the Aurora CPAP mask. Despite profitability challenges and a decline in U.S. sales, aftermarket trading saw a slight increase in shares as investors reacted to international expansion and new product launches.
Earnings call transcript: Inogen Q1 2026 shows revenue beat, EPS miss
Inogen Inc. (INGN) reported mixed Q1 2026 results, with revenue of $85.1 million ahead of forecasts by 3.34% due to strong international sales growth, while EPS missed predictions at -$0.30 against -$0.29. Despite the EPS miss, the stock saw a modest 0.7% increase in aftermarket trading, reflecting cautious optimism driven by the revenue beat and strategic product launches like the Aurora CPAP mask. The company reaffirms its 2026 revenue guidance, expecting stronger profitability in Q2 and Q3 due to seasonal trends and continued investment in new markets and product innovation.
Inogen (Nasdaq: INGN) Q1 2026 revenue up 3.4% as losses widen
Inogen reported a 3.4% increase in Q1 2026 revenue to $85.1 million, exceeding its outlook, driven by strong international portable oxygen concentrator demand and favorable foreign exchange rates, despite lower U.S. sales. However, GAAP net loss widened to $8.3 million and adjusted EBITDA became a loss of $1.4 million due to increased R&D investments. The company maintained its full-year 2026 revenue guidance of $366-$373 million and holds a strong cash position of $111.5 million with no debt.
Inogen: Q1 Earnings Snapshot
Inogen Inc. (INGN) reported a loss of $8.3 million in its first quarter, amounting to 30 cents per share. The company, which produces oxygen concentrators, generated $85.1 million in revenue during the period. This financial summary was generated using data from Zacks Investment Research.
